PMV PHARMACEUTICALS, INC. Operating Expenses
PMV PHARMACEUTICALS, INC. (PMVP) reported Operating Expenses of $18.88 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-14
- PMV PHARMACEUTICALS, INC. operating expenses for the quarter ending 2026-06-30 was $18.88M, a 17.47% decline year-over-year.
- PMV PHARMACEUTICALS, INC. operating expenses for the quarter ending 2026-03-31 was $19.02M, a 11.80% decline year-over-year.
- PMV PHARMACEUTICALS, INC. operating expenses for the quarter ending 2025-12-31 was $19.24M, a 23.55% decline year-over-year.
- PMV PHARMACEUTICALS, INC. operating expenses for the quarter ending 2025-09-30 was $22.52M, a 2.90% increase year-over-year.
- PMV PHARMACEUTICALS, INC. operating expenses for fiscal 2025 was $86.21M, a 0.89% increase from fiscal 2024.
- PMV PHARMACEUTICALS, INC. operating expenses for fiscal 2024 was $85.45M, a 6.63% increase from fiscal 2023.
- PMV PHARMACEUTICALS, INC. operating expenses for fiscal 2023 was $80.13M, a 4.01% increase from fiscal 2022.
- PMV PHARMACEUTICALS, INC. operating expenses for fiscal 2022 was $77.04M, a 32.16% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $18.88M 10-Q · filed 2026-08-14 | $37.90M 10-Q · filed 2026-08-14 | $57.14M derived: sum of 3 quarters · filed 2026-08-14 | $79.66M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $19.02M 10-Q · filed 2026-05-12 | $38.26M derived: sum of 2 quarters · filed 2026-05-12 | $60.78M derived: sum of 3 quarters · filed 2026-05-12 | $83.66M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $19.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $41.76M derived: sum of 2 quarters · filed 2026-03-06 | $64.64M derived: sum of 3 quarters · filed 2026-08-14 | $86.21M 10-K · filed 2026-03-06 |
| 2025-09-30 | $22.52M 10-Q · filed 2025-11-12 | $45.40M derived: sum of 2 quarters · filed 2026-08-14 | $66.96M 10-Q · filed 2025-11-12 | $92.13M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $22.88M 10-Q · filed 2026-08-14 | $44.44M 10-Q · filed 2026-08-14 | $69.61M derived: sum of 3 quarters · filed 2026-08-14 | $91.50M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $21.56M 10-Q · filed 2026-05-12 | $46.73M derived: sum of 2 quarters · filed 2026-05-12 | $68.62M derived: sum of 3 quarters · filed 2026-05-12 | $88.79M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $25.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $47.06M derived: sum of 2 quarters · filed 2026-03-06 | $67.23M derived: sum of 3 quarters · filed 2026-03-06 | $85.45M 10-K · filed 2026-03-06 |
| 2024-09-30 | $21.89M 10-Q · filed 2025-11-12 | $42.06M derived: sum of 2 quarters · filed 2025-11-12 | $60.28M 10-Q · filed 2025-11-12 | $79.18M derived: sum of 4 quarters · filed 2026-03-06 |
| 2024-06-30 | $20.17M 10-Q · filed 2025-08-07 | $38.39M 10-Q · filed 2025-08-07 | $57.29M derived: sum of 3 quarters · filed 2026-03-06 | $76.92M derived: sum of 4 quarters · filed 2026-03-06 |
| 2024-03-31 | $18.22M 10-Q · filed 2025-05-09 | $37.12M derived: sum of 2 quarters · filed 2026-03-06 | $56.75M derived: sum of 3 quarters · filed 2026-03-06 | $76.87M derived: sum of 4 quarters · filed 2026-03-06 |
| 2023-12-31 | $18.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $38.53M derived: sum of 2 quarters · filed 2026-03-06 | $58.65M derived: sum of 3 quarters · filed 2026-03-06 | $80.13M 10-K · filed 2026-03-06 |
| 2023-09-30 | $19.63M 10-Q · filed 2024-11-07 | $39.75M derived: sum of 2 quarters · filed 2024-11-07 | $61.23M 10-Q · filed 2024-11-07 | $82.39M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $20.12M 10-Q · filed 2024-08-08 | $41.60M 10-Q · filed 2024-08-08 | $62.76M derived: sum of 3 quarters · filed 2025-03-03 | $82.14M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $21.48M 10-Q · filed 2024-05-09 | $42.64M derived: sum of 2 quarters · filed 2025-03-03 | $62.02M derived: sum of 3 quarters · filed 2025-03-03 | $79.90M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $21.16M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $40.54M derived: sum of 2 quarters · filed 2025-03-03 | $58.42M derived: sum of 3 quarters · filed 2025-03-03 | $77.04M 10-K · filed 2025-03-03 |
| 2022-09-30 | $19.38M 10-Q · filed 2023-11-09 | $37.26M derived: sum of 2 quarters · filed 2023-11-09 | $55.88M 10-Q · filed 2023-11-09 | $74.35M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $17.89M 10-Q · filed 2023-08-09 | $36.50M 10-Q · filed 2023-08-09 | $54.98M derived: sum of 3 quarters · filed 2024-02-29 | $70.07M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $18.62M 10-Q · filed 2023-05-10 | $37.09M derived: sum of 2 quarters · filed 2024-02-29 | $52.19M derived: sum of 3 quarters · filed 2024-02-29 | $65.24M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $18.47M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $33.57M derived: sum of 2 quarters · filed 2024-02-29 | $46.62M derived: sum of 3 quarters · filed 2024-02-29 | $58.29M 10-K · filed 2024-02-29 |
| 2021-09-30 | $15.10M 10-Q · filed 2022-11-08 | $28.15M derived: sum of 2 quarters · filed 2022-11-08 | $39.82M 10-Q · filed 2022-11-08 | $50.32M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $13.05M 10-Q · filed 2022-08-09 | $24.72M 10-Q · filed 2022-08-09 | $35.23M derived: sum of 3 quarters · filed 2023-03-01 | $43.93M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $11.67M 10-Q · filed 2022-05-10 | $22.18M derived: sum of 2 quarters · filed 2023-03-01 | $30.88M derived: sum of 3 quarters · filed 2023-03-01 | $38.96M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $10.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $19.20M derived: sum of 2 quarters · filed 2023-03-01 | $27.29M derived: sum of 3 quarters · filed 2023-03-01 | $34.94M 10-K · filed 2023-03-01 |
| 2020-09-30 | $8.70M 10-Q · filed 2021-11-12 | $16.79M derived: sum of 2 quarters · filed 2021-11-12 | $24.44M 10-Q · filed 2021-11-12 | $31.80M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $8.09M 10-Q · filed 2021-08-13 | $15.74M 10-Q · filed 2021-08-13 | $23.09M derived: sum of 3 quarters · filed 2022-03-01 | $29.53M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $7.65M 10-Q · filed 2021-05-14 | $15.01M derived: sum of 2 quarters · filed 2022-03-01 | $21.45M derived: sum of 3 quarters · filed 2022-03-01 | |
| 2019-12-31 | $7.36M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $13.79M derived: sum of 2 quarters · filed 2022-03-01 | $26.64M 10-K · filed 2022-03-01 | |
| 2019-09-30 | $6.44M 10-Q · filed 2020-11-13 | $19.28M 10-Q · filed 2020-11-13 | ||
| 2018-12-31 | $18.89M 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |